|
|
Volumn 25, Issue 2, 2015, Pages 236-240
|
|
Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome
a
|
|
Author keywords
Benzimidazole; Cannabinoid receptor; CB2 agonist; Irritable bowel syndrome
|
|
Indexed keywords
ANALGESIC AGENT;
BENZIMIDAZOLE DERIVATIVE;
CANNABINOID 1 RECEPTOR;
CANNABINOID 2 RECEPTOR;
CANNABINOID 2 RECEPTOR AGONIST;
GASTROINTESTINAL AGENT;
RQ 00202730;
TRINITROBENZENESULFONIC ACID;
UNCLASSIFIED DRUG;
CANNABINOID RECEPTOR AGONIST;
ANALGESIA;
ANALGESIC ACTIVITY;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
AREA UNDER THE CURVE;
ARTICLE;
BODY TEMPERATURE;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG BIOAVAILABILITY;
DRUG CLEARANCE;
DRUG DOSE;
DRUG HALF LIFE;
DRUG IDENTIFICATION;
DRUG PENETRATION;
DRUG POTENCY;
DRUG SELECTIVITY;
DRUG SYNTHESIS;
EC50;
HUMAN;
HUMAN CELL;
HYPERALGESIA;
IN VITRO STUDY;
IN VIVO STUDY;
IRRITABLE COLON;
MAXIMUM PLASMA CONCENTRATION;
NONHUMAN;
RAT;
SINGLE DRUG DOSE;
STRUCTURE ACTIVITY RELATION;
TREATMENT RESPONSE;
VISCERAL PAIN;
VOLUME OF DISTRIBUTION AT STEADY-STATE;
AGONISTS;
ANIMAL;
CHEMISTRY;
IRRITABLE BOWEL SYNDROME;
MALE;
METABOLISM;
ORAL DRUG ADMINISTRATION;
TREATMENT OUTCOME;
RATTUS;
ADMINISTRATION, ORAL;
ANIMALS;
CANNABINOID RECEPTOR AGONISTS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
IRRITABLE BOWEL SYNDROME;
MALE;
RATS;
RECEPTOR, CANNABINOID, CB2;
TREATMENT OUTCOME;
|
|
EID: 84922231856
PISSN: 0960894X
EISSN: 14643405
Source Type: Journal
DOI: 10.1016/j.bmcl.2014.11.062 Document Type: Article |
|
Times cited : (29)
|
|
References (11)
|
